Michel Fabbro
Overview
Explore the profile of Michel Fabbro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
3022
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Freyer G, Floquet A, Tredan O, Carrot A, Langlois-Jacques C, Lopez J, et al.
Nat Commun
. 2024 Mar;
15(1):1985.
PMID: 38443333
Most patients with advanced ovarian cancer (AOC) ultimately relapse after platinum-based chemotherapy. Combining bevacizumab, olaparib, and durvalumab likely drives synergistic activity. This open-label phase 2 study (NCT04015739) aimed to assess...
12.
Fabbro M, Lamy P, Touraine C, Floquet A, Ray-Coquard I, Mollevi C
Front Oncol
. 2024 Jan;
13:1308630.
PMID: 38273857
HE4 and CA-125 are used for epithelial ovarian cancer (EOC) screening, diagnosis, and follow-up. Our objective was to study HE4 and CA-125 kinetics in patients treated for recurrent EOC. Serum...
13.
Lorusso D, Mouret-Reynier M, Harter P, Cropet C, Caballero C, Wolfrum-Ristau P, et al.
Int J Gynecol Cancer
. 2023 Dec;
34(4):550-558.
PMID: 38129136
Objective: In the PAOLA-1/ENGOT-ov25 trial (NCT02477644), adding maintenance olaparib to bevacizumab provided a substantial progression-free survival benefit in patients with newly diagnosed advanced ovarian cancer and homologous recombination deficiency (HRD)-positive...
14.
Vendrell J, Ban I, Solassol I, Audran P, Cabello-Aguilar S, Topart D, et al.
Int J Mol Sci
. 2023 Sep;
24(18).
PMID: 37762485
Purpose: The introduction of PARP inhibitors (PARPis) as a treatment option for patients with high-grade serous ovarian cancer (HGSOC) modified the approach of testing worldwide. In this study, we aim...
15.
Annakib S, Rigau V, Darlix A, Goze C, Duffau H, Bauchet L, et al.
Front Oncol
. 2023 Aug;
13:1212714.
PMID: 37534252
Purpose: The management of recurrent WHO grades II-III (rGII-III) glioma is not well established. This study describes the clinical outcomes in patients who received bevacizumab as rescue treatment. Methods: In...
16.
Blanc-Durand F, Yaniz-Galende E, Llop-Guevara A, Genestie C, Serra V, Herencia-Ropero A, et al.
Gynecol Oncol
. 2023 Jun;
175:194.
PMID: 37271667
No abstract available.
17.
Lequesne J, Joly F, Peron J, Ray-Coquard I, Hardy-Bessard A, Selle F, et al.
J Natl Compr Canc Netw
. 2023 May;
21(5):473-479.e4.
PMID: 37156482
Background: Current standards for toxicity reporting do not fully capture the impact of adverse events (AEs) on patients' quality of life (QoL). This study aimed to evaluate the association between...
18.
Mirza M, Lindahl G, Mahner S, Redondo A, Fabbro M, Rimel B, et al.
Cancer Res Commun
. 2023 Mar;
2(11):1436-1444.
PMID: 36970052
Significance: We retrospectively evaluated the mutational profile of HRR genes in tumor samples from 331 patients from the non-germline -mutated cohort of the phase III NOVA trial of patients with...
19.
Blanc-Durand F, Yaniz-Galende E, Llop-Guevara A, Genestie C, Serra V, Herencia-Ropero A, et al.
Gynecol Oncol
. 2023 Mar;
171:106-113.
PMID: 36868112
Rationale: Homologous recombination deficiency (HRD), defined as BRCA1/2 mutation (BRCAmut) or high genomic instability, is used to identify ovarian cancer (OC) patients most likely to benefit from PARP inhibitors. While...
20.
Quesada S, Solassol J, Ray-Coquard I, Fabbro M
Bull Cancer
. 2023 Mar;
110(4):371-381.
PMID: 36863920
High-grade serous ovarian carcinoma (HGSOC), the most frequent and aggressive form of epithelial ovarian cancer is characterized in half of cases by homologous recombination deficiency (HRD). This molecular alteration is...